Vaccine Clinical Trials Facilities Catalogue, 1990-2000

DRAFT

VACCINE CLINICAL TRIALS FACILITIES CATALOGUE, 1990-2000

NEW VACCINES AGAINST DESEASES OF SPECIAL NEED FOR THE THIRD WORLD (“DEVELOPING MARKET VACCINES”)*

WHO / INTERCLUSTER VACCINE RESEARCH INITIATIVE

Sources of information:

1) The WHO Vaccine and Biologicals Vaccine Trial Registry Directory, WHO V&B Vaccine Trial Registry (WHO/V&B/00.07, as of August 1999, available on the Internet at:

2) A PubMed/Medline-based vaccine clinical trials database prepared by Dr Taraz Samandari, Center for Vaccine Development, University of Maryland School of Medicine, USA from 1990 onwards, as of April 2000.

3) Communications from experts in the field of vaccine clinical trials, as of June 2000.

Vaccine Trials - DEVELOPMENT STATUS OF THE COUNTRY (NON INDUSTRIALIZED or INDUSTRIALIZED) Last date updated
DISEASE TARGET OF THE TESTED VACCINE*
Institution/s / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference/s
The Unit performing the vaccine trial / Country where the trial is conducted / Field site where the trial is conducted / Description of the specific vaccine / Year+ / Description of the specific vaccine / Year+ / Journal citation=Medline mainly
WHO/V&B/00.07
Expert communication, date

+Year during the trial was conducted/published (IP=In Progress; UD=Under Discussion)

[Note. Not shown: age category of participants, number of participants, collaborating Institutions]

* CHOLERA, DENGUE, ETEC, HIV, JAPANESE ENCEPHALITIS, LEISHMANIASIS, MALARIA, MENINGOCOCCUS A, SCHISTOSOMIASIS, SHIGELLOSIS, TUBERCULOSIS, TYPHOID

The Vaccine Clinical Trials Facilities Catalogue was established following a recommendation from a Pre-Task Force on Research and Development of the Global Alliance for Vaccines and Immunization (GAVI) during a meeting jointly convened with the WHO Intercluster Vaccine Research Initiative, 4-5 November 1999, Geneva, Switzerland.

Vaccine Trials - NON INDUSTRIALIZED COUNTRIES 15/06/00 18:04
CHOLERA (1)
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
Hospital Roberto del Rio / Chile / Santiago / CVD 103-HgR, live attenuated oral / 1991 / Rev Med Chil 1993;121:857
Centro para Vacunas en Desarrollo, Santiago / Chile / Santiago / CVD 103-HgR, live attenuated oral / 1997 / Pediatr Infect Dis J 1999;18:624
Ministry of Health, Santa Fe de Bogota / Colombia / Killed, oral cholera vaccine rBS/WC / 1992 / Bull Pan Am Health Organ 1995;4:312
WHO/V&B/00.07
Grupo de Genetica, Centro Nacional de Investigaciones Cientificas, Havana / Cuba / Vibrio cholerae 638 (El Tor, Ogawa) / 1999 / Genet Anal 1999;15:149
University of Indonesia, Department of Pediatrics, Jakarta / Indonesia / Rukun Warga / CVD 103-HgR, live attenuated oral / 1990 / Lancet 1992;340:689
National Instit. Health Res. & Devt., US Naval Medical Research / Indonesia / Jakarta / CVD 103-HgR, live attenuated oral / 1993 / Live, attenuated, lyophilized, oral cholera 01 vaccine, CVD 103-HgR / 1997 / J Infect Dis 1993;168:1169
WHO/V&B/00.07
Univ of Maryland, Center for Vaccine Development, Baltimore, USA / Mali / Sikasso / Live, attenuated, lyophilized oral cholera 01 vaccine, CVD 103-HgR / 1998 / Bull World Health Organ 1998;76: 63
WHO/V&B/00.07
National Institute of Public Health, School of Public Health, Mexico / Mexico / Jomulco and Jala, Nayarit State / Live oral attenuated (CVD103HgR)/ oral whole cell killed+purified B subunit cholera toxin (WCrBS) / 1994 / Expert communication, 05/00
US Naval Medical Research Unit, Detachment, Lima, Peru / Panama / NS / CVD103-HgR (classical, Inaba) and CVD111 (El Tor, Ogawa) / 1999 / Infect Immun 1999 Apr;67(4):2030
Peru / NS / CVD103-HgR (classical, Inaba) and CVD111 (El Tor, Ogawa) / 1997 / Infect Immun 1997 Sept;65(9):3852
US Army Medical Research Unit-Brazil, American / Peru / Ancon / Oral inactivated whole cell plus recombinant B subunit (WC/rBS) / 1992 / Trans R Soc Trop Med Hyg 1995;89(5):542
Universidad Peruana Cayetano Heredia, Lima / Peru / Canto Grande
Lima / . CVD103-HgR
. Oral inactivated whole cell plus recombinant B subunit (WC/rBS) / 1993 / Infect Immun 1993 Sep;61(9):3994-7
Vaccine 1995 May;13(7):691
Instituto de Investigacion Nutricional, Lima / Peru / Arequipa / Killed, oral cholera vaccine rBS/WC / 1995
IP / WHO/V&B/00.07
Walter Reed Army Institute of Research, Washington, DC, USA / Peru / NS / Inactivated whole-cell/recombinant-B-subunit (WC/rBS) / 1994 / Lancet 1994 Nov 5;344(8932):1273
Russian Research Inst Against Plague Problems (Microbe), Sazatov / Russia / NS / . Choleragen toxoid, Ogawa and Inaba O-antigens + some of V cholerae exoenzymes
. Choleragen toxoid, O-antigens of serovars Inaba and Ogawa / 1993
1991 / Zh Mikrobiol Epidemiol Immunobiol 1993;5:55
Zh Mikrobiol Epidemiol Immunobiol 1991; 7:55
Mahidol University,
Vaccine Trial Centre, Bangkok / Thailand / Bangkok / . LPS+cell-bound hemagg-lutinin+procholeragenoid vs. killed whole cell
. Live, attenuated, lyophilized/killed oral cholera 0139 vaccines / 1991
UD / Vaccine 1991;9:53
WHO/V&B/00.07
Epicentre, Paris, France / Uganda / Adjumani District / Killed, oral cholera vaccine / 1997 / WHO/V&B/00.07
Vaccine Trials - NON INDUSTRIALIZED COUNTRIES 15/06/00 18:04
CHOLERA (2)
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
National Institute of Hygiene and Epidemiology, Hanoi / Viet Nam / Hue / . Killed, oral cholera vaccine
. Bivalent cholera vaccine / 1993
IP / Lancet 1997 Jan 25;349(9047):231
WHO/V&B/00.07
Khanh Hoa Province / Killed, whole cell 01/0139 vaccine / 1997
1999 / WHO/V&B/00.07
Hanoi / Oral and bivalent cholera vaccines / 1995 / WHO/V&B/00.07
Vaccine Trials - NON INDUSTRIALIZED COUNTRIES 16/06/00 15:09
DENGUE
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
Mahidol University, Dept. of Microbiology, Bangkok / Thailand / Live, attenuated tetravalent dengue vaccine / 1994
1999
IP / J Infect Dis 1994 Jul;170(1):27
WHO/V&B/00.07
Vaccine 2000;18(S2):44
Expert communication, 06/00
Vaccine Trials - NON INDUSTRIALIZED COUNTRIES 16/05/00 11:10
ETEC
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
ICDDR-B, Bangladesh / Bangladesh / Dhaka / ETEC BSA-CF vaccine / UD / WHO/V&B/00.07
US Naval Medical Research Unit Number 3, Cairo / Egypt / Benha / Killed, oral ETEC recombinant cholera toxin B subunit vaccine / 1996
1997 / J Infect Dis 1998 Mar;177(3):796
J Infect Dis 1999 Jan;179(1):107
WHO/V&B/00.07
Abu Homos / Killed, oral ETEC recombinant cholera toxin B subunit vaccine / IP / WHO/V&B/00.07
Vaccine Trials - NON INDUSTRIALIZED COUNTRIES 12/06/00 16:18
HIV
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
Ministry of Public Health, Beijing / China / Longchuan County / Monovalent synthetic peptide vaccine (clade B, MN sequence) / 1997 / Asian Pac J Allergy Immunol 1997;15:105
Centro de Ingenieria Genetica y Biotecnologia, La Habana / Cuba / NS / MEP TAB9, containing six V3 epitopes / 1999 / Genet Anal 1999;15:149
Mahidol University, Bangkok / Thailand / NS / Remune (gp120 depleted inactivated virus, HZ321) / 1998 / Vaccine 1998;16:142
AIDS 1998;12:1521
Chulalongkorn University, Bangkok / Thailand / Bangkok / gp120 PND of HIV-1 MN / 1997 / Asian Pac J Allergy Immunol 1997;15:41
Vaccine Trials - NON INDUSTRIALIZED COUNTRIES 16/05/00 11:10
JAPANESE ENCEPHALITIS
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
Henan Provincial Institute of Parasitic Diseases, Zheng Zhou, Henan / China / Gusi County, Henan Province / Japanese Encephalitis vaccine / 1991 / Trans R Soc Trop Med Hyg 1994;88(6):632
Southeast Asian J Trop Med Public Health 1994;25(4):643
West China Univ. Medical Sciences, Dept. Pediatrics, and Chengdu Anti-epidemic Station, Sichuan / China / Live attenuated Japanese encephalitis vaccine (SA14-14-2) / 1995 / J Infect Dis 1997 Nov;176(5):1366-9
Central Research Institute, Japanese Encephalitis Vaccine Division, Kasauli / India / Mouse brain inactivated Japanese encephalitis vaccine / 1995 / Indian J Med Res 1995 Dec;102:267
Kaohsiung Medical College, Department of Pediatrics / Taiwan / JE simultaneous or not with MMR / 1999 / Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih 1999 May-Jun;40(3):161
Children's Hospital, Bangkok / Thailand / Pang Mabha District / Nakayama and Beijing strains JE vaccines / 1995 / Southeast Asian J Trop Med Public Health 1995 Dec;26(4):689
Vaccine Trials - NON INDUSTRIALIZED COUNTRIES 27/06/00 16:19
LEISHMANIA
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
Instituto de Ciencias Biologicas/Univ. Fed. de Minas Gerais, Dept. de Parasitologia, Belo Horizonte-MG / Brazil / Belo Horizonte / Nonliving polyvalent promastigote Leishmania vaccine 5 or Leishmania vaccine 6 +/- Corynebacterium parvum / 1990 / Infect Immun 1990;58:2198-203
Caratinga / (thimerosal-preserved, autoclaved, and lyophilized) of a killed Leishmania amazonensis / 1996 / Am J Trop Med Hyg 1999;61:294-5
Instituto Oswaldo Cruz, FIOCRUZ, Departamento de Protozoologia, Rio de Janeiro / Brazil / Caratinga / Autoclaved and nonautoclaved whole antigens from killed promastigotes of Leishmania amazonensis / 1999 / Vaccine 1999;17:1179-85
Universidad de Antioquia, Medellin / Colombia / Medellin / L amazonensis (whole parasite killed by merthiolate) / 1998 / L amazonensis (whole parasite killed by merthiolate) / UD / Expert communication, 06/00
Central Univ. Ecuador, Immun. Res. Lab., & Grad. School Basic Med. Sci., College of Medicine, Quito / Ecuador / Pichincha Province / Whole, killed promastigote (3 strains) + BCG adjuvant / 1997 / J Infect Dis 1998;177:1352-7
Kerman University of Medical Sciences, Medical School / Iran / Bam / Whole-cell autoclave-killed Leishmania major plus BCG / 1997 / Lancet 1998;351:1540-3
Bahar Medical Laboratory, Tehran / Iran / Killed Leishmania major vaccines +/- BCG / 1996 / Clin Dermatol 1996;14:489-95
Tehran Univ. Medical Sciences, Center for Research and Training in Skin Diseases and Leprosy, Thehran / Iran / Killed Leishmania / 1996 / Clin Dermatol 1996;14:497-502
Isfahan University of Medical Sciences / Iran / Isfahan / Killed (autoclaved) L. major promastigotes, ALM, mixed with BCG / 1999 / Vaccine 1999;17:466-72
Pasteur Institute, Tehran / Iran / NS / Autoclaved L major+BCG (whole cell) / 1999 / Expert communication, 06/00
Institute of Endemic Diseases, Khartoum / Sudan / Gedaref / Autoclaved L major+BCG / IP / Expert communication, 06/00
Universidad Central de Venezuela, Caracas / Venezuela / Killed leishmanial promastigotes, with or without BCG / 1994 / Vaccine 1994;12:1041-51
Vaccine Trials - NON INDUSTRIALIZED COUNTRIES 12/06/00 16:18
MALARIA
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
Escola Nacional de Saude Publica, Fundacao Oswaldo Cruz, Rio de Janeiro / Brazil / Costa Marques / SPf66, synthetic P. falcip peptide / 1996 / Am J Trop Med Hyg 1998;58:378
Rev Soc Bras Med Trop 1996;29:497
Inst de Inmunologia, Univ Nacional de Colombia, Bogota / Colombia / NS / SPf66, synthetic P. falcip peptide / 1992
1992
1994 / Vaccine 1992;10:179
Lancet 1993;341:705
Vaccine 1992;10:175
Clin Exp Immunol 1991;84:122
Vaccine 1996;14:1466
La Tola
Tumaco / SPf66, synthetic P. falcip peptide / 1992
1991
NS
Rosario River
Inst Colombiano de Medicina Tropical, Medellin / Colombia / Vigia del Fuerte/Bellavista / SPf66, synthetic P. falcip peptide / 1998 / Mem Inst Oswaldo Cruz 1998;93:495
Ministerio de Salud Publica, IIDES, Quito / Ecuador / La T / SPf66, synthetic P. falcip peptide / 1994 / Vaccine 1994;12:337
MRC Laboratories, Fajara / Gambia / Bakau / RTS,S/SBAS2 / 1998 / Am J Trop Med Hyg 1999;61:865
Parasite Immunol 1997;19:579
Lancet 1995;346:462
Basse / SPf66, synthetic P. falcip peptide / 1993
Upper River Division / SPf66, synthetic P. falcip peptide / 1994
Clinical Research Centre, Nairobi / Kenya / Western Kenya / Subunit circumsporozoite protein Asn-Ala-Asn-Pro tetrapeptide repeat-pseudomonas toxin A / 1991 / Vaccine 1996;14:817
US Army Medical Research Unit / Kenya / NS / R32tet32, recomb sporozoite protein / 1991 / Trans R Soc Trop Med Hyg 1991;85:336
Inst of Fundamental Studies, Kandy / Sri Lanka / NS / 185-200-kD peptides + 45-kD merozoite surface antigens covalently linked to diphtheria toxoid / 1995 / Clin Exp Immunol 1995;99:168
Hospital Clinic, Barcelona, Spain / Tanzania / Kilombero District / SPf66, synthetic P. falcip peptide / 1999 / Trop Med Int Health 1999;4:368
Ifakara Centre and Headquarters, National Institute for Medical Research, Ifakara / Tanzania / Kilombero District / SPf66, synthetic P. falcip peptide / 1994
1995 / Lancet 1994;344:1175
J Infect Dis 1996;174:367
Shoklo Malaria Research Unit, Mae Sot / Thailand / Thai-Burma border / SPf66, synthetic P. falcip peptide / 1997 / SPf66, synthetic P. falcip peptide / 1995 / Am J Trop Med Hyg 1997;56:526
Lancet 1996;348:701
Mahidol University, Bangkok / Thailand / Bangkok / SPf66, synthetic P. falcip peptide / 1997 / Acta Trop 1997;67:215
US Armed Forces Research Instit., Bangkok / Thailand / Thai-Burma border / R32Tox-A / 1994 / Vaccine 1994;12:102
Universidad Central de Venezuela, Caracas / Venezuela / South Venezuela / SPf66, synthetic P. falcip peptide / 1994 / J Infect Dis 1994;170:396
Vaccine Trials - NON INDUSTRIALIZED COUNTRIES 28/06/00 17:40
MENINGOCOCCUS A
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
John Radcliffe Hospital, Oxford, United Kingdom / MRC Laboratories, Fajara, Gambia / Gambia / NS / Meningococcal A+C polysaccharide / 1992 / Vaccine 1999;17:3086-93
Medical Research Council (MRC) Laboratories, Fajara / Gambia / Upper River Division / Meningococcal A+C polysaccharide and
CRM197 conjugated / 1992 / J Infect Dis 1995;171:632-8
Eastern region / Meningococcal A+C polysaccharide and
diphteria conjugate vaccines / 1997 / J Infect Dis 1997;175:200-4
Centre de Recherche sur les Méningites et les Schistosomiases (CERMES) / Niger / Niamey / Meningococcal A+C diphteria-toxoid conjugated and Meningococcal A+C polysaccharide / 1997
2000 / WHO/V&B/00.07
Pediatr Infect Dis J 2000;19:144-50
King Saud University, Department of Pediatrics, College of Medicine, Riyadh / Saudi Arabia / Mecca / Meningococcal A+C polysaccharide / 1994 / Ann Trop Paediatr 1994;14;275
Vaccine Trials - NON INDUSTRIALIZED COUNTRIES 28/06/00 17:40
SCHISTOSOMIASIS
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
Institut Pasteur, Lille, France / / Senegal / Saint Louis / Sh28GST / 1998
IP / Expert communication, 06/00
Vaccine Trials - NON INDUSTRIALIZED COUNTRIES 16/05/00 11:10
SHIGELLA
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
ICDDR-B, Bangladesh / Bangladesh / Matlab / Shigella flexneri 2a vaccine / IP / WHO/V&B/00.07
Israel Defence Force, Medical Corps / Israel / . Live, oral E. coli K12-S. flexneri 2a vaccine (EcSf2a-2)
. S. sonnei and S. flexneri 2a polysaccharide conjugated to rEPA
. O-specific polysaccharide of S. sonnei conjugated to rEPA / 1994
1999 / S. sonnei and S. flexneri 2a polysaccharide conjugates / 1994 / Vaccine 1999 Aug 6;17(23-24):3109
Lancet 1997 Jan 18;349(9046):155
Infect Immun 1996 Oct;64(10):4074
Vaccine 1994 Nov;12(15):1436
Schneider Children's Medical Center of Israel, Petah Tikva / Israel / S. sonnei and S. flexneri 2a polysaccharide conjugates / 1999 / J Infect Dis 1999 Jun;179(6):1565
Karolinska Institute, Dept.Immunology, Microb., Path. & Infect. Diseases, Huddinge Hospital, Sweden / Viet Nam / Hanoi / Live, auxotrophic S. flexneri vaccine strain SFL124 / 1993
1994 / Vaccine 1993;11(2):180
J Infect 1994 Jan;28(1):11
Vaccine Trials - NON INDUSTRIALIZED COUNTRIES 28/06/00 13:25
TUBERCULOSIS
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
Universidad Nacional de Rosario, Rosario / Argentina / NS / M vaccae (SRL 172) / 1999 / Respir Med 1999;93:557-63
Universidade Federal de Bahia, Salvador-Bahia / Brazil / BCG / IP / Expert communication, 06/00
MRC Laboratories, Fajara / Gambia / Banjul / BCG / IP / WHO/V&B/00.07
Tahleghari Pulmonary Diseases Hospital, Mashad / Iran / Mashad / M vaccae / Lancet 1992;340:1360-1
Faculty of Medicine Kuwait Univ, Safat / Univ College, London, UK / Kuwait / Safat / M vaccae R877R / 1990 / Tubercle 1990; 2:87-93
LEPRA, Chilumba / Malawi / Karonga District / BCG +/- M leprae / 1995 / Lancet 1996;348:17-24
Infectious Diseases Hospital Kano / Univ College, London, UK / Nigeria / Kano / M vaccae / 1991 / Respir Med 1995;89:199-207
Institutul de Ftiziologie, Bucharest / Romania / NS / M vaccae / 1997 / Respir Med 1997;91:13-9
Respir Med 1997;91:21-9
MRC National Tuberculosis Research Program, Pretoria / South Africa / Durban / M vaccae / 1996 / Lancet 1999;354:116-9
Uludag University Medical School, Bursa / Turkey / Bursa / BCG / 1991 / Arch Dis Child 1992;67:80
Gazi University, Ankara / Turkey / NS / BCG / 1995 / Tuber Lung Dis 1995;76:248
Mulago Hospital & Makerere Univ, Kampala / Case Western Reserve Univ, Cleveland, USA / Uganda / Kampala / M vaccae / 2000 / J Infect Dis 2000;181:1304-12
Vaccine Trials - NON INDUSTRIALIZED COUNTRIES 16/05/00 11:10
TYPHOID
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
China / Guanxi / Typhoid Vi vaccine / UD / WHO/V&B/00.07
Centro para Vacunas en Desarrollo, Santiago, Chile / Chile / Santiago / Typhoid Vi purified polysaccharide vaccine / 1997 / WHO/V&B/00.07
University of Nairobi, Department of Medical Microbiology, Nairobi / Kenya / Bungoma / Purified Vi polysaccharide (Typhim Vi) / 1995 / East Afr Med J 1995 Mar;72(3):162
Catholic University Medical College, Department of Internal Medicine and Pediatrics, Seoul / Korea / Vi capsular polysaccharide / 1995 / J Korean Med Sci 1995 Oct;10(5):314
Chachoengsao Hospital, Chachoengsao / Thailand / Live, oral attenuated, Ty21a / 1992 / J Infect Dis 1992 Aug;166(2):451
Vaccine Trials - INDUSTRIALIZED COUNTRIES 16/05/00 11:10
CHOLERA
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
University of Adelaide Department of Medicine, Adelaide / Australia / Adelaide / Live oral hybrid vaccine organism Salmonella typhi Ty21a/V. cholerae Inaba / 1991 / Vaccine 1991;9:515
University of Vienna, Institute for Specific Prophylaxis and Tropical / Austria / Vienna / CVD 103-HgR and Ty21a, live oral attenuated / 1996 / Infect Immun 1996 Apr;64(4):1454
University of Goteborg, Goteborg / Sweden / . Oral B subunit-whole cell (B-WC)
. B subunit-killed whole cell Vibrios (B-WC)
. Oral bivalent B subunit-O1/O139 whole cell (B-O1/O139 WC) / 1992
1993
1994
1996 / Vaccine 1992;10(2):130
Vaccine 1993;11(10):1007
Vaccine 1994 Sep;12(12):1078
Vaccine 1996 Oct;14(15):1459
Johns Hopkins Univ. School of Hyg. & Public Health, Baltimore / USA / . Live oral, Peru-15
. Killed, oral cholera vaccine rBS/WC / 1997
IP / J Infect Dis 1997 Jul;176(1):201
WHO/V&B/00.07
University of Maryland, Center for Vaccine Development, Baltimore / USA / Baltimore
Maryland
Ohio / . CVD 103-HgR, live attenuated oral
. CVD 112, live attenuated oral
. CVD 111, live attenuated oral / 1991
1992
1995
1997
1999 / Vaccine 1994 Aug;12(11):1000
Infect Immun 1992 Oct;60(10):4430
J Infect Dis 1992 Oct;166(4):837
J Infect Dis 1995 Sep;172(3):883
Am J Trop Med Hyg 1997 May;56(5):533
Infect Immun 1999 Dec;67(12):6341
US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland / USA / Washington / . Bengal-3, Bengal-15, and VRI-16, MO10, live attenuated Vibrio cholerae
. Peru-15, live attenuated oral / 1994
1995 / Lancet 1995 Apr 15;345(8955):949
J Infect Dis 1995 Oct;172(4):1126
Walter Reed Army Institute of Research, Washington, DC / USA / Washington / . Oral, inactivated whole cell plus recombinant B subunit (WC/rBS)
. Peru-3, Bang-3, and Bah-3 live, oral, attenuated / 1991
1994 / J Infect Dis 1993 Jun;167(6):1446
J Infect Dis 1994 Dec;170(6):1518
Vaccine Trials - INDUSTRIALIZED COUNTRIES 16/06/00 15:08
DENGUE
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
Armed Forces Research Institute of Medical Sciences, APO AP 96546 / USA / NS / Live-attenuated dengue 2 (strain 16681 PDK 53) / 1994 / Vaccine 1996;14:329
University of Maryland, Center for Vaccine Development, Baltimore / USA / Washington / . Dengue-1 (45AZ5) further attenuated in primary dog kidney cell cultures
. Live, attenuated tetravalent dengue vaccine / 1994
1999 / J Infect Dis 1994;170:1448
Expert communication, 06/00
Vaccine Trials - INDUSTRIALIZED COUNTRIES 16/05/00 11:10
ETEC
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
University of Göteborg, Goteborg / Sweden / Goteborg / Oral cholera toxin B subunit (rCTB) CFA ETEC / 1996
IP / Vaccine 1995;13:1754-1758
Vaccine 1998;16(2/3):255-260
WHO/V&B/00.07
University of Maryland, Center for Vaccine Development, Baltimore / USA / CFA II encapsulated in biodegradable polymer microspheres / 1994 / Vaccine 1994 Nov;12(14):1270
Vaccine Trials - INDUSTRIALIZED COUNTRIES 12/06/00 16:32
HIV (1)
Institution / Study Country / Study site/s / Phase I-II / Year / Phase III-IV / Year / Reference
St.Vincent's Hospital, University of New South Wales, Sidney / Australia / . Synthetic, monovalent, octameric HIV-1MN V3 peptide
. p24 virus-like particle (p24-VLP) / 1997
1998 / AIDS Res Hum Retroviruses 1997;13:29
AIDS 1998;12:175
ICPMR, Westmead Hospital, Department of Clinical Immunology, Wentworthville / Australia / p24 virus-like particle (p24-VLP) / 1999 / AIDS Res Hum Retroviruses 1999;15:105
McGill AIDS Centre, Montreal General Hospital, Quebec / Canada / VaxSyn (rgp160 of HIV-1IIIB) / 1998 / AIDS Res Hum Retroviruses 1998;14:483
Hopital Saint Antoine, Paris / France / prime=rV gp160; boost=soluble gp 160 / 1991 / J Acquir Immune Defic Syndr 1992;5:539
Universite Paris, CHU Cochin, Paris / France / . prime= MN/LAI (rgp160); boost=V3 (MN) linear peptide
. prime=ALVAC-HIV (vCP205);boost=p24E-V3 MN synthetic peptide / 1995
1999 / AIDS Res Hum Retroviruses 1995;12:1479
AIDS Res Hum Retroviruses 1999;15:633
Institut Pasteur, Paris / France / . prime=ALVAC-HIV (vCP125); boost= MN/LAI (rgp160)
. prime=canarypox virus exprssg HIV envelope gp160; two boosts=recomb env protein / 1995
1996 / AIDS Res Hum Retroviruses 1995;11:373
J Infect Dis 1996;174:734
Universite P et M Curie, Paris / France / Tat toxoid / 1998 / Biomed Pharmacother 1998;52:431
University of Munich / Germany / VaxSyn (rgp160 of HIV-1IIIB) / 1996 / AIDS 1999;13:1461
Hannover Medical School / Germany / anti-CD4 idiotype / 1999 / Vaccine 1999;17:1837
University of Rome, La Sapienza / Italy / rgp160 / 1997
1998 / J Infect Dis 1997;176:904
AIDS 1998;12:473
IRCCS Maggiore Hosp & State Univ. of Milan / Italy / Tat toxoid / 1998
1999 / J Hum Virol 1998;1:293
J Acquir Immune Defic Syndr Hum Retrovirol 1999;20